Protocol Ledger

NCT06450041 · Phase II · RECRUITING

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Interventional Phase II clinical trial protocol NCT06450041 sponsored by New Approaches to Neuroblastoma Therapy Consortium in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-16 Enrollment: 62 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06450041
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)62 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06450041
Protocol FieldVerified Registry Value
NCT IdentifierNCT06450041
Consolidated Lead SponsorNew Approaches to Neuroblastoma Therapy Consortium
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment62 participants (ESTIMATED)
Registered Start Date2024-12-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI